Next Article in Journal
Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients
Next Article in Special Issue
Left Ventricular Function and Myocardial Triglyceride Content on 3T Cardiac MR Predict Major Cardiovascular Adverse Events and Readmission in Patients Hospitalized with Acute Heart Failure
Previous Article in Journal
Associations between Daily Step Counts and Physical Fitness in Preschool Children
Previous Article in Special Issue
Ceruloplasmin, NT-proBNP, and Clinical Data as Risk Factors of Death or Heart Transplantation in a 1-Year Follow-Up of Heart Failure Patients
Open AccessReview

Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?

1
Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria
2
Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK
3
Institute of Pharmaceutical Sciences, University of Graz, 8020 Graz, Austria
4
Department of Laboratory Medicine, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 164; https://doi.org/10.3390/jcm9010164 (registering DOI)
Received: 10 December 2019 / Revised: 30 December 2019 / Accepted: 5 January 2020 / Published: 7 January 2020
(This article belongs to the Special Issue Novel Biomarkers for Heart Disease)
Background: Heart failure (HF) remains one of the leading causes of death to date despite extensive research funding. Various studies are conducted every year in an attempt to improve diagnostic accuracy and therapy monitoring. The small cytoplasmic heart-type fatty acid-binding protein (H-FABP) has been studied in a variety of disease entities. Here, we provide a review of the available literature on H-FABP and its possible applications in HF. Methods: Literature research using PubMed Central was conducted. To select possible studies for inclusion, the authors screened all available studies by title and, if suitable, by abstract. Relevant manuscripts were read in full text. Results: In total, 23 studies regarding H-FABP in HF were included in this review. Conclusion: While, algorithms already exist in the area of risk stratification for acute pulmonary embolism, there is still no consensus for the routine use of H-FABP in daily clinical practice in HF. At present, the strongest evidence exists for risk evaluation of adverse cardiac events. Other future applications of H-FABP may include early detection of ischemia, worsening of renal failure, and long-term treatment planning. View Full-Text
Keywords: H-FABP; heart-type fatty acid-binding protein; FABP3; fatty acid-binding protein 3; heart failure; HF; cardiac biomarkers H-FABP; heart-type fatty acid-binding protein; FABP3; fatty acid-binding protein 3; heart failure; HF; cardiac biomarkers
Show Figures

Graphical abstract

MDPI and ACS Style

Rezar, R.; Jirak, P.; Gschwandtner, M.; Derler, R.; Felder, T.K.; Haslinger, M.; Kopp, K.; Seelmaier, C.; Granitz, C.; Hoppe, U.C.; Lichtenauer, M. Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far? J. Clin. Med. 2020, 9, 164.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop